Aurinia Pharmaceuticals (AUPH) Tops Q1 EPS by 6c ; Offers Guidance

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of $0.25, $0.06 better than the analyst estimate of $0.19. Revenue for the quarter came in at $77.7 million versus the consensus estimate of $75.29 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2026 revenue of $315-325 million, versus the consensus of $326.2 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Faraday Future reveals robot lineup and new products at Automate
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings